- Home
- ACAD
as 08-01-2025 4:00pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Upcoming Earnings Alert:
Get ready for potential market movements as ACADIA Pharmaceuticals Inc. ACAD prepares to release earnings report on 06 Aug 2025.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.5B | IPO Year: | 2004 |
| Target Price: | $27.94 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.40 - $25.23 | Next Earning Date: | 08-06-2025 |
| Revenue: | $996,283,000 | Revenue Growth: | 22.42% |
| Revenue Growth (this year): | 13.28% | Revenue Growth (next year): | 10.88% |
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brege Laura | ACAD | Director | Jun 4 '25 | Sell | $21.78 | 14,446 | $314,633.88 | 15,095 | |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | May 16 '25 | Sell | $22.50 | 4,000 | $90,000.00 | 22,395 | |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | May 16 '25 | Sell | $25.00 | 2,000 | $50,000.00 | 62,130 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $22 From $19, Maintains Perform Rating
Business Wire
a month ago
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Argus Research
a month ago
ACAD: What does Argus have to say about ACAD?
TipRanks
a month ago
Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital
MT Newswires
a month ago
RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $26, Keeps Outperform Rating
Insider Monkey
a month ago
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
Simply Wall St.
a month ago
High Growth Tech Stocks In The US Market June 2025
Simply Wall St.
a month ago
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three years
Compare ACAD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.